Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rocket Pharmaceuticals Inc (RCKT)

Rocket Pharmaceuticals Inc (RCKT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 370,119
  • Shares Outstanding, K 108,222
  • Annual Sales, $ 0 K
  • Annual Income, $ -258,750 K
  • EBIT $ -250 M
  • EBITDA $ -241 M
  • 60-Month Beta 0.66
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.15

Options Overview Details

View History
  • Implied Volatility 124.30% (-56.89%)
  • Historical Volatility 59.68%
  • IV Percentile 59%
  • IV Rank 11.29%
  • IV High 577.24% on 06/30/25
  • IV Low 66.68% on 02/19/25
  • Expected Move (DTE 14) 0.81 (23.61%)
  • Put/Call Vol Ratio 1.08
  • Today's Volume 100
  • Volume Avg (30-Day) 228
  • Put/Call OI Ratio 0.35
  • Today's Open Interest 19,485
  • Open Int (30-Day) 22,604
  • Expected Range 2.61 to 4.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.42
  • Number of Estimates 7
  • High Estimate -0.39
  • Low Estimate -0.46
  • Prior Year -0.62
  • Growth Rate Est. (year over year) +32.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.81 +22.60%
on 11/21/25
3.47 -0.72%
on 12/05/25
+0.13 (+3.77%)
since 11/05/25
3-Month
2.81 +22.60%
on 11/21/25
4.51 -23.60%
on 10/15/25
+0.16 (+5.03%)
since 09/05/25
52-Week
2.19 +57.31%
on 05/27/25
15.00 -77.03%
on 12/11/24
-9.88 (-74.14%)
since 12/05/24

Most Recent Stories

More News
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need,...

RCKT : 3.43 (+0.29%)
Rocket Pharmaceuticals: Q3 Earnings Snapshot

Rocket Pharmaceuticals: Q3 Earnings Snapshot

RCKT : 3.43 (+0.29%)
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

Pivotal Phase 2 trial of RP-A501 for Danon disease to resume in 1H 2026 KRESLADIâ„¢ for severe LAD-I on track for March 28, 2026 PDUFA date ...

RCKT : 3.43 (+0.29%)
Biologics Market Surges Toward $680B as FDA Accelerates Approval Pathways

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The global biologics industry is experiencing unprecedented expansion as the market surges toward $679.56...

AVAI : 0.2950 (-0.03%)
VRTX : 460.95 (+0.78%)
WST : 280.13 (-0.58%)
RCKT : 3.43 (+0.29%)
AXSM : 149.99 (+1.32%)
Rocket Pharmaceuticals’ FDA Resubmission for KRESLADI™ Accepted

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Rocket Pharmaceuticals...

RCKT : 3.43 (+0.29%)
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADIâ„¢ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)

Prescription Drug User Fee Act (PDUFA) target action date is March 28, 2026 All primary and secondary endpoints were met, and KRESLADIâ„¢ was well tolerated ...

RCKT : 3.43 (+0.29%)
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need,...

RCKT : 3.43 (+0.29%)
Rocket Pharmaceuticals Board Member Resigns in September

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. The latest...

RCKT : 3.43 (+0.29%)
Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Summit Therapeutics (SMMT) and United Therapeutics (UTHR)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Rocket Pharmaceuticals (RCKT – Research Report), Summit Therapeutics (SMMT – Research Report) and United...

SMMT : 18.68 (-0.69%)
RCKT : 3.43 (+0.29%)
UTHR : 483.54 (-0.12%)
Rocket Pharmaceuticals Withdraws FDA Application for Gene Therapy

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Rocket Pharmaceuticals...

RCKT : 3.43 (+0.29%)

Business Summary

Rocket Pharmaceuticals, Inc. is an emerging, clinical-stage biotechnology company. It focused on developing first-in-class gene therapy treatment options for rare, undertreated diseases. Rocket Pharmaceuticals Inc., formerly known as Inotek Pharmaceuticals Corporation, is based in LEXINGTON, United States....

See More

Key Turning Points

3rd Resistance Point 3.62
2nd Resistance Point 3.54
1st Resistance Point 3.48
Last Price 3.43
1st Support Level 3.34
2nd Support Level 3.26
3rd Support Level 3.20

See More

52-Week High 15.00
Fibonacci 61.8% 10.11
Fibonacci 50% 8.60
Fibonacci 38.2% 7.08
Last Price 3.43
52-Week Low 2.19

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar